PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients
Metrics: PDF 680 views | HTML 1249 views | ?
Wei Wang1, Ge Shen1, Shikai Wu1, Shiping Song1, Yanli Ni1, Zhuoyao Suo1, Xiangying Meng1, Dan Li1, Lin Zhou1, Rimin Hao1, Yaowei Zhao1, Li Bai1, Lili Hou1, Bing Liu1 and Guangxian Liu1
1Cancer Therapy Center, Affiliated Hospital of The Academy of Military Medical Sciences, Beijing 100071, China
Guangxian Liu, email: email@example.com
Bing Liu, email: firstname.lastname@example.org
Keywords: PD-1, peripheral immune cells, immunomodulation, radiation therapy, cancer
Received: June 15, 2016 Accepted: January 16, 2017 Published: February 02, 2017
Immune checkpoint inhibitors that block the PD-1/PD-L1 signaling pathway have been used to treat a wide variety of cancers. Although results have been promising, significant inter-individual and inter-tumor variability has been observed. It is believed that better clinical outcome could be achieved if the treatment was individually designed based on the functional status of the PD-1/PD-L1 signaling and the cellular immunity. In this study, we analyzed the mRNA expression of PD-1 and other immunomodulatory genes in peripheral blood from cancer patients, and immunomodulatory gene expression during radiotherapy and immunomodulation therapy with cytokines. Our results show that the PD-1 mRNA expression is significantly increased in peripheral blood in cancer patients. Anti-cancer treatments can significantly modulate the PD-1 expression, but this is largely dependent on the initial immune status. Moreover, the PD-1 expression on peripheral lymphocytes can be immunoactivation-derived. These results suggest that the regulation and expression pattern of PD-1/PD-L1 signal is complicated which will influence the effect of blockade of the PD-1/PD-L1 signaling pathway for cancer treatment. Through combined analysis of PD-1, CTLA-4, and other immune markers in peripheral blood, we may accurately evaluate the functional status of PD-1/PD-L1 signaling and cellular immunity, thereby providing clues for guiding anti-PD-1 or anti-PD-L1 treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.